Lenvatinib with pembrolizumab for previously treated metastatic non-small cell lung cancer

Lenvatinib with pembrolizumab is in development for the treatment of metastatic non-small cell
lung cancer (NSCLC). NSCLC is the most common form of lung cancer. Metastatic NSCLC
describes tumours that have spread from the lungs to other parts of the body. Smoking tobacco
is the cause of most lung cancers and the biggest risk factor. Other risk factors include second hand smoke, exposure to workplace carcinogens, radiation exposure, environmental pollution,
and family history of lung cancer. Current standard of care treatment can help to control the
cancer for some time and reduce symptoms, however, sometimes NSCLC can continue to grow
despite chemotherapy and immunotherapy.